Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00516737
First received: August 13, 2007
Last updated: August 12, 2014
Last verified: August 2014
Results First Received: March 12, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Migraine
Interventions: Drug: Comparator: rizatriptan benzoate
Drug: Comparator: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Phase III First Patient In: 03-October-2007 Last Patient Last Visit: 08-April-2008 13 outpatient centers worldwide (10 United States, 3 Germany)

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants were assessed, using the protocol inclusion and exclusion criteria, at Visit 1, and if eligible were randomized at that same visit.

Reporting Groups
  Description
Rizatriptan 10 mg ODT Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
Placebo Matching placebo; one dose, treatment of a single migraine attack

Participant Flow:   Overall Study
    Rizatriptan 10 mg ODT     Placebo  
STARTED     103     104  
COMPLETED     92     96  
NOT COMPLETED     11     8  
Lost to Follow-up                 2                 0  
Physician Decision                 0                 1  
Withdrawal by Subject                 0                 1  
Lack of Qualifying Event                 9                 6  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Rizatriptan 10 mg ODT Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
Placebo Matching placebo; one dose, treatment of a single migraine attack
Total Total of all reporting groups

Baseline Measures
    Rizatriptan 10 mg ODT     Placebo     Total  
Number of Participants  
[units: participants]
  103     104     207  
Age  
[units: years]
Mean ( Full Range )
  41  
  ( 19 to 69 )  
  44  
  ( 18 to 66 )  
  42.5  
  ( 18 to 69 )  
Gender  
[units: participants]
     
Female     90     96     186  
Male     13     8     21  
Race/Ethnicity, Customized  
[units: participants]
     
Black or African American     4     3     7  
White     95     100     195  
Asian     2     1     3  
Multi-Racial     2     0     2  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Who Are Pain Free at 2 Hours Post-Dose   [ Time Frame: 2 hours post-dose ]

2.  Secondary:   Number of Participants With 24-Hour Sustained Pain Freedom   [ Time Frame: 24 hours post-dose ]

3.  Secondary:   Number of Participants With no Rescue Use up to 24 Hours Post-Dose   [ Time Frame: 24 hours post-dose ]

4.  Secondary:   Number of Participants With Absence of Photophobia at 2 Hours Post-dose   [ Time Frame: 2 hours post-dose ]

5.  Secondary:   Number of Participants With Absence of Phonophobia at 2 Hours Post-dose   [ Time Frame: 2 hours post-dose ]

6.  Secondary:   Number of Participants With Absence of Nausea at 2 Hours Post-dose   [ Time Frame: 2 hours post-dose ]

7.  Secondary:   Number of Participants With Absence of Functional Disability at 2 Hours Post-Dose   [ Time Frame: 2 hours post-dose ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
In the Adverse Events section, all non-serious adverse experiences reported are post-treatment, up to the time of taking rescue medication or 14 days post-dose, whichever comes first.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp.
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@merck.com


Publications:

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00516737     History of Changes
Other Study ID Numbers: 0462-081, 2007_547
Study First Received: August 13, 2007
Results First Received: March 12, 2009
Last Updated: August 12, 2014
Health Authority: United States: Food and Drug Administration